ChemCon Passes its Fourth FDA Inspection - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ChemCon Passes its Fourth FDA Inspection



ChemCon, a Freiburg, Germany-based contract research company that offers custom synthesis of APIs and fine chemicals, has announced that it successfully passed an FDA inspection.

The March 2014 inspection for GMP compliance was the fourth in the 17-year history of the company. The inspection examined all quality assurance systems of the company relating to production, equipment,manufacturing facilities, materials, and quality controls. No form 483 was issued, the quality systems were considered acceptable, and the inspection was classified as no action indicated, the company reports.

Source: ChemCon

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here